Ludwig, Cassie A.
Vail, Daniel
Al-Moujahed, Ahmad
Callaway, Natalia F.
Saroj, Namrata
Moshfeghi, Andrew
Moshfeghi, Darius M.
Funding for this research was provided by:
Research to Prevent Blindness
National Eye Institute (NEI P30-EY026877, NEI P30-EY026877)
Michels Fellowship Foundation
Article History
Received: 23 October 2022
Accepted: 19 May 2023
First Online: 9 June 2023
Competing interests
: Darius M. Moshfeghi has the following conflicts of interest: 1-800 Contacts (board of directors, equity), Akceso Advisors AG (evaluation of DME market), Akebia (scientific advisory board for ROP), Alcon (data safety monitoring board for HAWK/HARRIER), Aldeyra Therapeutics (Site PI: ADX-2191-PVR-001 GUARD), Allegro (scientific advisory board), Apellis (Site PI: APL2-303 DERBY), Bayer Pharma AG (ROP imaging committee), CMEOutfitters.com (CME consultant), Cole Eye Institute (CME consultant), Congruence medical solutions (consultant), dSentz, Inc. (founder, board of directors, equity), Genentech (PROPER grant 2019), Grand Legend Technology, LTD (equity), Iconic Therapeutics (steering committee, unpaid), Irenix (scientific advisory board, unpaid), Linc (founder, equity, board of directors), Northwell Health (grand rounds), Novartis Pharmaceuticals (data safety monitoring board for HAWK/HARRIER, KITE/KESTREL, China nAMD/DME, pediatric advisory board), Ocular Surgery News (consultant), Pr3vent (founder, board of directors, equity), Praxis UNS, Inc. (consultant), Prime Medical Education (CME consultant), Promisight, Inc. (founder, board of directors, equity), Pykus (scientific advisory board, equity), Regeneron (CME consultant, ROP steering committee, PI for ROP trial), Retina Technologies LLC (advisor, consultant), Retina Today/Pentavision (consultant), Shapiro Law Group (ROP expert witness), SLACK, Inc. (CME consultant), University of Miami (CME consultant), VersI, Inc. (founder, equity), Vindico (CME consultant), Visunex (scientific advisory board, equity. Namrataa Saroj has the following conflicts of interest: Apellis (Consultant); Allegro (Consultant, equity); Amgen (Consultant); iRenix (Consultant, equity); RegenxBio (Consultant); SamaCare (Consultant, equity); Pr3vent (Equity). None of the other authors report conflicts of interest.